Physician
Pathology
Dr. Kenneth D. Aldape, MD
|
|
Give Review
Kenneth D. Aldape is an expert in the field of Pathology. He studied medicine at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a one of the best medicals schools. University of California San Francisco School of Medicine is ranked 3/3 in Research/PrimaryCare. Dr. Kenneth D. Aldape is a published doctor as well. He has 100 publications published. The latest was: The role of neuropathology in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.
- The role of neuropathology in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
- Distinct Pathways in the Pathogenesis of Sebaceous Carcinomas Implicated by Differentially Expressed MicroRNAs.
- IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
- Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis.
- Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors.
- Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
- Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
- Germline mutations in shelterin complex genes are associated with familial glioma.
- C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.
- Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.
- Identification of Causal Genetic Drivers of Human Disease through Systems-Level Analysis of Regulatory Networks.
- Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
- Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.
- International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading.
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
- Lambrolizumab induced central nervous system (CNS) toxicity.
- Characteristics and survival of patients with advanced cancer and p53 mutations.
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
- Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing.
- Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
- Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
- ACVR1 mutations and the genomic landscape of pediatric diffuse glioma.
- A randomized trial of bevacizumab for newly diagnosed glioblastoma.
- IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors.
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial.
- The Somatic Genomic Landscape of Glioblastoma.
- Using the Molecular Classification of Glioblastoma to Inform Personalized Treatment.
- Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.
- SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
- Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma.
- The Cancer Genome Atlas Pan-Cancer analysis project.
- EGF-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion.
- Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagn...
- Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target.
- Brain metastases from papillary thyroid carcinomas.
- Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
- ?v?8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion.
- ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.
- Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma.
- Forkhead box M1 is regulated by heat shock factor 1 and promotes glioma cells survival under heat shock stress.
- EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis.
- Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma.
- Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
- Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.
- Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
- Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
- The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
- Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
- NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
- Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
- Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor.
- Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by Stat3 inhibition.
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
- Caspase-3 cleavage links delta-catenin to the novel nuclear protein ZIFCAT.
- Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors.
- Multigene sets for clinical application in glioma.
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
- Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article.
- NFKBIA deletion in glioblastomas.
- Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.
- Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed gli...
- Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation.
- A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
- Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.
- FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
- Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
- HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
- Association and interactions between DNA repair gene polymorphisms and adult glioma.
- VEGF Trap induces antiglioma effect at different stages of disease.
- Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma.
- Long-term anti-inflammatory and antihistamine medication use and adult glioma risk.
- Exploratory analysis of the copy number alterations in glioblastoma multiforme.
- Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor co...
- Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma.
- Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy.
- Aggregation of cancer in first-degree relatives of patients with glioma.
- Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.
- Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors.
- Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.
- Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 express...
- Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix.
- Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
- Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
- Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation.
- FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells.
- Activation of stat3 in human melanoma promotes brain metastasis.
- Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.
- The molecular epidemiology of gliomas in adults.
- YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
- Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma.
- Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of hum...
- Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.
- The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.
Schools
Univ Of Ca
Uc San Francisco
Doctors Specialties
- Neuropathology
- Pathology
Accepted Insurances
- Basic HMO
- Vitalidad Plus California Con Aetna
- American Republic
- Cigna
- Commercial Insurance Company
- Coventry Health Care
- GEHA
- HealthSmart
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
UCSF -
University of California San Francisco School of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083700801 |
| Last Name Of The Provider | ALDAPE |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
|
Dr. Clifford D. Sauls, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur W. Bracey Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robyn A. Beach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John H. Connelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel L. Grimmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael H. Covinsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet M. Bruner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren A. Langford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne Z. Powell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sozos Papasozomenos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adriana Olar, MD
This Doctor is OpenDoctor Recommended.
|